DOX?NOP1 HCl
Code | Size | Price |
---|
TAR-T27200-100mg | 100mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27200-500mg | 500mg | Enquire | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C
Images
Documents
Further Information
Bioactivity:
DOX-NOP1 is a molecular hybrid covalently joining doxorubicin (DOX) and NOP1. DOX-NOP1 showed similar increased toxicity toward resistant cancer cells and, in addition, lower cardiotoxicity than DOX.
CAS:
T27200
Molecular Weight:
973.31
Purity:
0.98
SMILES:
O=C(C1=C(C2=C(C(O)=C1C3=O)C[C@@](O)(C(COC(C4=CC=C(C(NCCCNC5=CC(C(F)(F)F)=C([N+]([O-])=O)C=C5)=O)C=C4)=O)=O)C[C@@H]2O[C@@H]6O[C@H]([C@H]([C@H](C6)N)O)C)O)C7=C3C=CC=C7OC.[H]Cl
References
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance Konstantin ChegaevAurore FraixElena GazzanoGamal Eldein F. Abd-EllatefMarco BlangettiBarbara RolandoSabrina ConociChiara RigantiRoberta FrutteroAlberto GascoSalvatore Sortino Publication Date (Web): January 30, 2017 (Letter) doi: 10.1021/acsmedchemlett.7b00016